Poor adherence to therapy is a major reason that large percentage of patients with hypertension fail to achieve good blood pressure control. Side effects, such as cough, dizziness, nausea, and ...
BELLEVUE, WASHINGTON AND MENLO PARK, CALIFORNIA — Kona Medical (www.konamedical.com) announced the initiation of the WAVE IV clinical trial of its non-invasive Surround Sound® Hypertension Therapy ...
The Gemini Study was a 14-week, open-label, non-comparative, office-based, multicenter trial to evaluate single-pill therapy in the treatment of concomitant hypertension and dyslipidemia. In addition ...
Atrioventricular interval modulation (AVIM) therapy for hypertension may help address this common comorbidity among patients with pacemakers. For patients with pacemakers, hypertension is a common ...
Orchestra BioMed Holdings, Inc. presented key insights on its atrioventricular interval modulation (AVIM) therapy for managing high-risk hypertension at the CSI 2025 Meeting. The therapy aims to ...
Please provide your email address to receive an email when new articles are posted on . Women with type 2 diabetes have a higher risk for CVD events if they are diagnosed with hypertension before age ...
Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...
Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – fits into the treatment ...
The FDA has granted Breakthrough Device Designation to Orchestra BioMed's Atrioventricular Interval Modulation (AVIM) therapy, aimed at treating patients with uncontrolled hypertension who are at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback